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Quality of life is an important treatment outcome for conditions that are rarely fatal, such as cutaneous basal
cell carcinoma and squamous cell carcinoma (typically called nonmelanoma skin cancer (NMSC)). The purpose
of this study was to compare quality-of-life outcomes of treatments for NMSC. We performed a prospective
cohort study of 633 consecutive patients with NMSC diagnosed in 1999 and 2000 and followed for 2 years after
treatment at a university-based private practice or a Veterans Affairs clinic. The main outcome was tumor-related
quality of life 1 to 2 years after therapy, measured with the 16-item version of Skindex, a validated measure.
Skindex scores vary from 0 (best) to 100 (worst) in three domains: Symptoms, Emotions, and Function.
Treatments were electrodessication and curettage (ED&C) in 21%, surgical excision in 40%, and Mohs surgery in
39%. Five hundred and eight patients (80%) responded after treatment. Patients treated with excision or Mohs
surgery improved in all quality-of-life domains, but quality of life did not improve after ED&C. There was no
difference in the amount of improvement after excision or Mohs surgery. For example, mean Skindex Symptom
scores improved 9.7 (95% CI: 6.9, 12.5) after excision, 10.2 (7.4, 12.9) after Mohs surgery, and 3.4 (0.9, 7.6) after
ED&C. We conclude that, for NMSC, quality-of-life outcomes were similar after excision and Mohs surgery, and
both therapies had better outcomes than ED&C.
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INTRODUCTION
Basal cell carcinoma and squamous cell carcinoma of the
skin, typically called nonmelanoma skin cancer (NMSC), are
the most common malignancies. The conventional goal of
treatment is prevention of tumor recurrence, but quality of life
and costs are also important outcomes because NMSC only
rarely affects survival.
Existing data about outcomes are insufficient to guide
therapy for most NMSCs (Thissen et al., 1999; Bath-Hextall
et al., 2004), and there is substantial unexplained variation in
performance rates of therapies in different settings (Chren
et al., 2004). Each of the common therapies can prevent
recurrence for many NMSCs (NCCN, 2005; Rubin et al.,
2005). Some data indicate that recurrence rates are lowest
after Mohs surgery (Rowe, 1995; Smeets et al., 2004b), but
early results of a recent randomized trial for basal cell
carcinomas demonstrated no significant difference in tumor
recurrence at 30 months after excision or Mohs surgery
(Smeets et al., 2004a), findings that have been controversial
(Otley, 2005). With respect to costs, electrodessication and
curettage (ED&C) is the least expensive therapy (Joseph et al.,
2001); in a recent European cost comparison, Mohs surgery
was significantly more costly than excision (Essers et al.,
2006), results that conflict with other findings (Cook and
Zitelli, 1998; Welch et al., 1999). Finally, although NMSC is
highly prevalent and generally nonfatal, the specific effects of
treatments on quality of life are not known.
The purpose of this work was to measure and compare
quality-of-life outcomes of the three most common therapies
for basal cell carcinoma and squamous cell carcinoma of the
skin. We performed a prospective cohort study of 633
consecutive patients with NMSC diagnosed in 1999 and
2000 and followed for 2 years after treatment at a university-
based private practice or a Veterans Affairs (VA) clinic. The
main outcome was tumor-related quality of life 1 to 2 years
after therapy, measured with the 16-item version of Skindex
(Chren et al., 2001). Skindex scores vary from 0 (best) to 100
(worst) in three domains: Symptoms, Emotions, and Function.
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RESULTS
Baseline characteristics
Patients treated with the three therapies were similar in age,
but patients treated with Mohs surgery were more likely than
those treated with ED&C or excision to be female, with
smaller tumors, located in the H-zone of the face. Patients
treated with excision were more likely to be poor, to have
had squamous cell carcinomas, and to have been treated at
the VA. Before therapy, patients whose tumors were
ultimately treated with Mohs surgery reported worse Emo-
tional quality-of-life effects of their tumors than patients
treated with the other therapies (Table 1).
Change in tumor-related quality of life at 2 years after therapy
Of 633 patients, 508 (80%) responded about tumor-related
quality of life at 12, 18, or 24 months after treatment. Those
who responded after treatment were similar to nonresponders
in multiple characteristics examined, including age, gender,
income, baseline tumor-related quality of life, tumor type,
tumor diameter, tumor location on the body, type of treatment
received, and whether the treatment was performed by an
attending physician, resident physician, or nurse practitioner.
Within-treatment group comparisons. Patients treated with
excision or Mohs surgery experienced statistically significant
(Po0.05) improvements in all three quality-of-life domains
after therapy (Figure 1, Table 2). For example, after excision
and Mohs surgery, mean adjusted Symptoms scores improved
by 9.7 and 10.2 points, respectively, and Emotions scores
improved by 18.6 and 21.7 points, respectively. Patients
treated with ED&C experienced no change in tumor-related
quality of life.
Table 1. Characteristics of 633 patients with nonrecurrent NMSCs1
Type of therapy
Characteristic ED&C (n=136) Excision (n=251) Mohs (n=246) P
Patient characteristics
Age in years, mean7SD 65 (16) 68 (14) 65 (15) 0.085
Gender male (%) 79 82 70 0.005
Annual income less than $30,000 (%) 45 61 52 0.011
Health status (SF-12)
Physical Component Score, mean7SD 46.1 (12.2) 44.8 (11.8) 46.2 (11.1) 0.374
Mental Component Score, mean7SD 49.3 (11.0) 48.3 (11.2) 48.5 (10.7) 0.673
Comorbidity (Charlson index), mean7SD 2.1 (2.7) 2.3 (2.8) 2.2 (3.1) 0.768
History of previous NMSC (%) 60 57 48 0.032
Baseline Skindex subscale scores (7SD)
Symptoms 19.6 (23.6) 21.7 (23.2) 21.8 (23.5) 0.651
Emotions 33.0 (28.0) 38.9 (30.4) 46.3 (27.0) o0.0001
Functioning 12.1 (21.7) 15.1 (24.6) 14.0 (21.1) 0.482
Number of NMSCs at enrollment, mean7SD 1.3 (0.7) 1.2 (0.6) 1.4 (0.9) 0.088
Tumor characteristics
Histological type (%)
Basal cell carcinoma 82 69 83 0.001
Squamous cell carcinoma 18 31 17
Tumor diameter, mm, mean7SD 9.3 (5.4) 12.0 (13.4) 8.6 (5.8) 0.0006
Tumor present in the ‘H-zone’ of the face, % 11 32 71 o0.001
Characteristics of care
Treating clinician type (%)
Attending physician 61 47 98 o0.0001
Resident physician 30 52 2
Nurse practitioner 9 1 0
Practice site, private practice (%) 60 37 60 o0.001
ED&C, electrodessication and curettage; NMSC, nonmelanoma skin cancer; SD, standard deviation.
1Number of missings for each characteristic: age 0, gender 0, income 46, health status 47, comorbidity 0, history of NMSC 0, symptoms 14, emotions 3,
functioning 5, number of NMSCS 0, histological type 0, diameter 85, H-zone 1, treating clinician type 29, practice site 0.
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Between-treatment group comparisons: entire sample. In
pair-wise comparisons of the treatment groups, both excision
and Mohs surgery were significantly better than ED&C in
improvements in Symptoms, Emotions, and Functioning
(Table 3). For example, for the Emotional domain, the
difference in mean adjusted change scores for excision and
Mohs surgery compared to ED&C was 13.2 and 16.3,
respectively (Pp0.001). Smaller but statistically significant
pair-wise differences were found between both excision and
Mohs surgery compared to ED&C for the Symptoms and
Functioning domains. Excision and Mohs surgery did not
differ, however, in their effects on any domain of tumor-
related quality of life (Table 3). These findings were similar in
subgroups of tumors located on the face (n¼ 326), or on other
parts of the body (results not shown).
Between-treatment group comparisons based on propensity
for treatment. Similar results were also found in subgroups of
patients matched for propensity for treatment (Table 4). For
the Emotional domain, both excision and Mohs surgery
resulted in improved scores compared to ED&C; differences
in Symptoms and Functioning were not significant. There was
no difference comparing excision and Mohs surgery in mean
adjusted change scores in any domain of tumor-related
quality of life.
DISCUSSION
In patients with NMSC, tumor-related quality of life
improved after excision or Mohs surgery but not after
ED&C. Moreover, for all domains of tumor-related quality
of life, the improvement was similar after excision and
Mohs surgery, two common therapies that vary significantly
in cost.
Despite the prevalence of NMSC, there is no evidence-
based consensus about optimal therapy for the majority of
tumors (Thissen et al., 1999; Bath-Hextall et al., 2004). In
fact, we have previously reported significant variation in
treatments for NMSC in different practice sites (Chren et al.,
2004). Mohs surgery was over twice as likely to be performed
in a private setting as in a VA clinic, even though all therapies
were available at both sites and many clinicians practiced at
both sites. This variation was unexplained by patient, tumor,
or clinician variables that might likely affect treatment
choice. The current study, comparing quality of life in
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Figure 1. Quality-of-life outcomes of treatment for NMSC. For groups of
patients with NMSC treated with ED&C, excision, or Mohs surgery,
mean scores of the (a) symptoms, (b) emotions, and (c) functioning subscales
of Skindex-16 are plotted over time from before treatment for NMSC, to
2 years after treatment.
Table 2. Improvement in Skindex scores after treatments for NMSC: within-treatment group comparisons
Improvement in Skindex score after therapy, mean (95% confidence interval)
Unadjusted Adjusted1
Treatment group (n) Symptoms Emotions Functioning Symptoms Emotions Functioning
ED&C (105) 3.8 [0.1,7.7] 3.2 [1.1, 7.5] 0.42 [3.8, 3.1] 3.4 [0.9,7.6] 5.4 [0.2,11.0] 1.92 [6.0,2.3]
Excision (204) 8.5**** [5.6,11.5] 16.9**** [13.2,20.6] 4.2** [1.7,6.7] 9.7*** [6.9,12.5] 18.6*** [15.1,22.2] 3.3* [0.7,5.9]
Mohs (195) 9.6**** [6.5,12.7] 23.8**** [20.3,27.3] 5.3*** [2.5,8.1] 10.2*** [7.4,12.9] 21.7*** [18.1,25.3] 5.0*** [2.4,7.6]
ED&C, electrodessication and curettage; NMSC, nonmelanoma skin cancer.
1Adjusted for age, gender, income, history of previous NMSC, baseline Skindex subscale score, tumor type, tumor diameter, tumor location in the H-zone of
the face, treatment type, whether the treatment was performed by an attending physician, resident physician, or nurse practitioner, and whether the practice
setting was the private or the VA site.
2Negative score indicates worsening in Skindex score.
*Significantly different change from pretreatment value, Pp0.05.
**Significantly different change from pretreatment value, Pp0.01.
***Significantly different change from pretreatment value, Pp0.001.
****Significantly different change from pretreatment value, Pp0.0001.
www.jidonline.org 1353
M-M Chren et al.
Outcomes of Nonmelanoma Skin Cancer
different treatment groups, contributes important data about
outcomes to inform a consensus about care for NMSC.
The inferiority of electrodessication/curettage compared to
the other treatments with respect to improving tumor-related
quality of life is not surprising. ED&C often leaves scars that
are larger than the tumor being treated, and which may
themselves affect skin-related quality of life.
The similarity in improvement in tumor-related quality of
life after excision and Mohs surgery is important and is
consistent across quality-of-life domains. The results are
surprising because, conventionally, a major advantage to
Mohs surgery is believed to be that it is ‘‘tissue-sparing,’’ in
that tissue without histological evidence of tumor is
preserved. Our finding is consistent, however, with results
from a recent randomized trial for basal cell carcinoma in
which the two therapies were found to have similar cosmetic
outcomes (Smeets et al., 2004a) and similar generic quality-
of-life outcomes (Essers et al., 2006).
In addition, our results expand the previous findings about
quality of life after NMSC therapy. The previous study had
compared the responses of a subset of patients in a
randomized trial (110 patients, 27% of the sample) to two
generic instruments (Essers et al., 2006). Overall changes in
the scores were very small. This finding is not surprising as
generic instruments may lack sensitivity to quality-of-life
effects of specific conditions (Patrick and Deyo, 1989). Using
a skin-specific instrument we demonstrated that, in a
substantially larger sample of patients, both excision and
Mohs surgery improved tumor-related quality of life in all
domains, and that ED&C did not improve quality of life in any
domain.
In the US, NMSC is the fifth most costly cancer to treat in
the Medicare population (after lung, prostate, colon, and
breast) (Housman et al., 2003), and Mohs surgery is
commonly used (overall, about 30% of facial basal cell
carcinomas are treated with Mohs surgery (Smeets, 2005)).
ED&C is the least expensive method of treatment. A recent
European cost comparison using microcosting techniques
determined that costs for Mohs surgery were significantly
higher than those of excision (average costs $898 vs $700
(@0.79 Euros/dollar)) (Essers et al., 2006). Given the high
prevalence of NMSC and the difference in costs among
Table 3. Differences in Skindex scores after treatments for NMSC: between-treatment group comparisons in entire
sample
Differences between treatment groups in Skindex scores after treatment, mean (95% confidence interval)1
Unadjusted Adjusted2
Comparison Symptoms Emotions Functioning Symptoms Emotions Functioning
Excision vs ED&C 4.7 [0.2,9.7] 13.7**** [7.7,19.7] 4.6* [0.3,8.8] 6.3* [1.3,11.3] 13.2*** [6.8,19.7] 5.2* [0.4,10.0]
Mohs vs ED&C 5.8* [0.8,10.8] 20.6**** [14.9,26.3] 5.7* [1.1,10.2] 6.8* [1.5,12.1] 16.3*** [9.4,23.3] 6.9** [1.7,12.0]
Mohs vs excision 1.1 [3.2,5.3] 7.0** [1.9,12.1] 1.1 [2.7,4.8] 0.5 [3.9,4.9] 3.1 [2.6,8.8 1.7 [2.5,5.8]
ED&C, electrodessication and curettage; NMSC, nonmelanoma skin cancer.
1Positive difference indicates first treatment had improved score compared with second treatment.
2Adjusted for age, gender, income, history of previous NMSC, baseline Skindex subscale score, tumor type, tumor diameter, tumor location in the H-zone of
the face, treatment type, whether the treatment was performed by an attending physician, resident physician, or nurse practitioner, and whether the practice
setting was the private or the VA site.
*Significantly different mean change scores between treatment groups, Pp0.05.
**Significantly different mean change scores between treatment groups, Pp0.01.
***Significantly different mean change scores between treatment groups, Pp0.001.
****Significantly different mean change scores between treatment groups, Pp0.0001.
Table 4. Differences in Skindex scores after treatments for NMSC: between-treatment group comparisons in pairs
matched for propensity for treatment
Differences between treatment groups in Skindex scores after treatment, mean (95% confidence interval)1
Comparison (No. of pairs) Symptoms Emotions Functioning
Excision vs ED&C (51 pairs) 1.6 [9.8,6.7] 13.2* [3.3,23.1] 3.1 [3.5,9.8]
Mohs vs ED&C (24 pairs) 9.2 [2.1,20.5] 23.6** [10.1,37.2] 3.7 [4.6,12.0]
Mohs vs excision (81 pairs) 4.0 [3.1,11.1] 3.4 [3.8,10.7] 4.2 [2.3,10.8]
1Positive difference indicates first treatment had improved score compared with second treatment; negative difference indicates first treatment had worse
score compared with second treatment.
*Significantly different mean change scores between treatment groups, P=0.0230.
**Significantly different mean change scores between treatment groups, P=0.0029.
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treatments, the similarity of quality-of-life outcomes after
excision and Mohs has potentially important health policy
implications.
This observational study of effectiveness was not a
randomized trial, and patients and tumors differed in the
three treatment groups. Comparisons were adjusted for
baseline differences, however, and the results were similar
after analyses using propensity score techniques that per-
mitted comparison of patients with similar measured covari-
ates for the performance of different treatments. On the other
hand, unmeasured factors could have affected both choice of
therapy and quality-of-life outcomes. For example, we did
not measure patients’ pretreatment preferences or expecta-
tions for different therapies (which may affect patient-
reported outcomes) (Peck et al., 2001). It is likely, however,
that these aspects of patients’ experience affect patient
satisfaction with therapy, rather than tumor-related quality
of life, which was the outcome measured in this study.
Finally, although the sample is typical of most patients with
NMSC, the study was conducted in a single city at one
academic program, and may not be generalizable to other
locations.
Conclusion
For NMSC, quality-of-life outcomes were similar after two
common therapies, excision and Mohs surgery, and both
therapies had better outcomes than ED&C. Although Mohs
surgery is the most expensive therapy, it is thought to be
worth the extra costs, in part because it is ‘‘tissue-sparing’’.
We found that patients did not perceive any difference in the
effects of tumor or treatment on their well-being after Mohs
surgery compared with excision, even after adjusting for
many features of patient, tumor, and care. Although
evidence-based care for NMSC will require long-term data
about tumor recurrence, these results about quality-of-life
outcomes can inform decisions by physicians and patients
about these common nonfatal cancers.
MATERIALS AND METHODS
Design, setting, and subjects
This study was approved by the Committee on Human Research of
the University of California at San Francisco, according to the
Declaration of Helsinki Principles. Tumors were identified by daily
review of pathology records at both hospitals. A dermatopathologist
was available at both sites. Nonmelanoma skin cancers were defined
as those with final histopathological diagnoses of basal cell
carcinoma or squamous cell carcinoma. Because recurrent NMSCs
are considered more aggressive and at significantly higher risk for
poor outcomes than are primary tumors, we eliminated 204 tumors
described by the clinician in the medical record as ‘recurrent’ or
‘possibly recurrent’. We also eliminated 61 tumors that were treated
with uncommon therapies such as laser or cryotherapy. The total
number of patients with nonrecurrent NMSC treated with the
three major therapies at the two hospitals during the study period
was 1314.
Patients with tumors diagnosed during the study period were
enrolled if they had a current mailing address and if, before
treatment, they responded to a questionnaire about their tumor-
related quality of life. Participants gave their written informed
consent. The sample for this study consisted of those 633 patients on
which quality-of-life responses were available before treatments. A
minority (130 patients, 21%) had more than one tumor diagnosed at
enrollment; to measure tumor-related quality of life specific to a
single tumor, we asked each patient to respond only about effects
related to the tumor that bothered him or her the most. Patients who
were enrolled were similar to those not enrolled in age, tumor
histological type, tumor diameter, tumor location on the body, and
type of treatment received. Enrolled patients were, however, more
likely to be male (77 vs 69% of those not enrolled, P¼ 0.002), to
have had a history of previous NMSC (54 vs 47%, P¼ 0.016), to
have been treated at the VA (49 vs 31%, Po0.0001), and to have
had the tumor biopsy performed by a nurse practitioner (19 vs 12%,
P¼ 0.001). No data were collected about tumors that were
diagnosed after enrollment.
Data collection and measures
Chart information. Using structured dataforms, trained research
staff collected data from clinician notes and pathology records. Data
about tumors included clinical descriptions and location on the
body, including whether they were located in the ‘H’ zone of the
face, a cosmetically important location on the mid-face in which
tumors are believed also to be at particularly high risk for recurrence
(Swanson et al., 1983).
Survey instrument. All patients were surveyed by mail before
treatment and at 1 week, 6 weeks, and 3, 12, 18, and 24 months after
treatment. Patients’ reports of sociodemographic characteristics,
health status, and comorbidity were measured before treatment;
tumor-related quality of life was measured before and at each point
after treatment. Annual income was assessed by a patient’s response
to a single item; response choices were six categories of income,
from less than $15,000 to more than $75,000; for comparisons, these
data were dichotomized to less than or greater than or equal to
$30,000 (the median income of the sample).
Health status was measured with an adapted version of the
Medical Outcomes Study SF-12 instrument (Ware et al., 1996).
Scores on the SF-12 are reported as a Physical Component Summary
Scores and a Mental Component Summary Score; on these scales,
higher is healthier and norm-based standardized scores have means
of 50 in the general US population. Comorbidity was measured by a
version of the Charlson instrument adapted for patient response
(Charlson et al., 1987; Katz et al., 1996).
Tumor-related quality of life before therapy and at all points after
treatment was measured with the 16-item version of Skindex, a
validated measure (Chren et al., 2001). Skindex-16 inquires about
potential effects of skin conditions on quality of life; patients choose
from seven response choices, anchored by ‘‘Never bothered’’ and
‘‘Always bothered’’. For example, items inquire about itching,
hurting, worry, frustration, and effects on daily activities. Skindex
responses are reported as three subscales, addressing three domains:
Symptoms, Emotional effects, and effects on social and physical
Functioning; scores vary from 0 (least effect on quality of life) to 100
(most effect on quality of life). For this study, patients were asked to
respond specifically about quality-of-life effects of their skin cancer
and its treatment; we did not specifically inquire about the quality-
of-life effects of scar compared to other potential results of the
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treatment. To ensure that patients responded over time about quality-
of-life effects of the same tumor (even if they had multiple tumors,
either at enrollment or subsequently), for each patient with multiple
tumors we used a map on which the tumor in question was marked.
In addition, the instructions prompted patients to respond about the
tumor that was treated ‘‘x’’ months ago (at the time of enrollment in
the study).
The minimal clinically meaningful change in Skindex scores was
determined as follows. In 485 patients from the sample, Skindex-16
scores before and 1 week after treatment were compared with their
responses to a global question with seven response choices about
overall bother from the skin cancer. A difference in one response
choice to the global question was assumed to correspond to the
minimal clinically meaningful difference (Guyatt et al., 1993, 2002;
Juniper et al., 1994; Sprangers et al., 2002). Based on this analysis,
the minimal clinically meaningful difference in all Skindex subscales
was 10 points, and changes for improvement or deterioration were
similar.
Analytic strategy
Our analytic strategy was, first, to compare baseline clinical features
of patients and tumors treated with the three therapies. Differences
between treatment groups were evaluated using Fisher’s exact test
for dichotomous variables, w2 test for categorical variables, and
analysis of variance for continuous variables.
For each Skindex subscale and each patient, we defined change
in tumor-related quality of life after treatment as the average
difference between the baseline subscale score, and the subscale
scores at 12, 18, or 24 months. The rationale for this strategy was that
quality of life likely stabilizes after 12 months after treatment, and
using the average of the three time points permitted us to include
patients who responded at any of the final follow-up times.
We used multivariable models to evaluate changes in tumor-
related quality of life after treatment, adjusted for pretreatment
features. To accommodate unequal numbers of follow-up observa-
tions from patients, we used mixed effects models, with random
effects corresponding to each patient. For each subscale, we
modeled the change from baseline subscale score to the subscale
score after treatment. In adjusted models, we included the following
explanatory variables: age, gender, income, history of previous
NMSC, baseline Skindex subscale score, tumor type, tumor
diameter, tumor location in the H-zone of the face, treatment type,
whether the treatment was performed by an attending physician,
resident physician, or nurse practitioner, and whether the practice
setting was the private or the VA site.
Because of differences in observed characteristics in the three
treatment groups, we also used propensity score methods to adjust for
differences between patients that would relate to choice of treatment
(Rubin, 1997; D’Agostino, 1998). We calculated propensity scores
for patients in each of the three pair-wise treatment comparisons
(excision vs ED&C, Mohs surgery vs ED&C, and Mohs surgery vs
excision). These propensity scores were determined using a logistic
regression model for treatment in which independent variables
included all patient, tumor, and care characteristics that were
associated with actual treatment choice in bivariable analyses, or
that we thought might likely be associated with treatment choice.
These variables were patient age, gender, income, history of previous
NMSC, baseline Skindex Emotions subscale score, tumor type, tumor
diameter, tumor location in the H-zone of the face, presence of
histological risk factors for tumor recurrence (NCCN, 2005), whether
the patient had more than one NMSC, whether the biopsy was
performed by an attending physician, resident physician, or nurse
practitioner, and whether the practice setting was the private or the
VA site. For each of the three pair-wise comparisons, we created
matched pairs of patients based on propensity score, using a Greedy
5-to 1 digit-matching algorithm (Parsons, 2001). We then compared
change in Skindex-16 scores in the groups of matched pairs.
Statistical analyses were performed using Stata Statistical Soft-
ware, Release 9.
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